Summary

It is well-known that inflammation plays a major role in the genesis of the atherosclerotic plaque and thus favours the occurrence of stroke. But, inflammation is also involved after an ischaemic event affecting the brain. In this case, one can observe the infiltration of numerous inflammatory cells at the site of the lesion, the activation of the microglia and of pro-inflammatory cytokines, etc. It is usually thought that this post-stroke inflammation is rather deleterious, as suggested by the fact that, after an experimentally-induced ischaemic stroke, blockade of the inflammatory response improves the neurological condition of mice. Nevertheless, until now, the application of such experimental treatments in humans has revealed unsuccessful. One of the possible explanations for this phenomenon might be that inflammation also has some beneficial effects, such as clearance of damaged tissue, promotion of angiogenesis, or still tissue remodelling and regeneration.

After this first “basic science” part, we will briefly review some clinical aspects of the most significant inflammatory diseases that can cause stroke, i.e., the vasculitis. Among them, Takayasu’s arteritis, giant cell temporal arteritis (Horton’s disease), and primary angiitis of the central nervous system will be discussed. We will also shortly address the question of the antiphospholipid syndrome.

*Key words: cytokines; ischaemia; microglia; neuroprotection; vasculitis.*

Inflammatory mechanisms related to an ischaemic stroke

**Brain ischaemia**

Stroke is a leading cause of long-term disability and remains the third cause of death in developed countries (World Health report 2007, World Health Organisation). While haemorrhagic stroke triggers cerebral oedema and inflammation, this short review focuses on the more common ischaemic stroke. Importantly, while...
ischaemia at first induces only a loss of function at its very early stages, structural damage appears rapidly thereafter and progresses as minutes and hours go by. Reduction of cerebral blood flow leads to a lack of oxygen and glucose supply to the brain parenchyma. This nutrient deficiency triggers multiple events including a dramatic depletion of ATP, perturbation of the cellular ionic homeostasis, neurotransmitter release and activation of many cytotoxic enzymes. The release of the excitatory neurotransmitter glutamate leads to excessive excitotoxic stimulation of glutamate receptors in energy deprived neurons. Excitotoxicity is a major mechanism in the early stages of the progression of ischaemic brain injury. Other detrimental events include peri-infarct depolarisation, apoptosis and inflammation (fig. 1) [1, 2].

Several therapeutic strategies aimed at decreasing the effect of these ischaemia-induced phenomena have been successful in animal stroke models, but not so far in stroke patients. The only successful treatment in the acute phase for stroke patients is thrombolysis, the goal of which is to restore the blood flow to the brain [3, 4]. As it needs to be administered intra-venously within 3 hours to 4.5 hours or intra-arterially within 6 hours from symptom onset it is limited to a small number of patients [5]. Beyond this time-window restoring cerebral blood flow is no longer beneficial and there is an increased risk of developing a symptomatic intracerebral haemorrhage [6]. Furthermore, the recombinant tissue plasminogen activator (rtPA) enhances excitotoxicity and increases the lesion volume in our mouse MCAo model [7, 8]. Thus, there is a need for new treatments for the patients who can not be thrombolysed.

An important delayed mechanism beginning within hours from the onset of ischaemia is the robust inflammatory response in the ischaemic tissue. There is increasing evidence showing a detrimental effect of the post-ischaemic inflammatory reaction [9, 10]. Therefore therapeutic strategies targeting the delayed inflammatory response could inhibit the progression of the tissue damage providing an extended therapeutic window for neuroprotection.

Neuroinflammatory response after ischaemia

The brain immune defence system is essential to protect neurons against infectious agents. In cerebral ischaemia, the inflammatory response plays a role in the clearance of cell debris; however it also enhances the damage to the tissue. An immune response at the site of injury is characterised by the infiltration, accumulation and activation of inflammatory cells. Within hours after the onset of focal cerebral ischaemia peripheral leukocytes adhere to the cerebral endothelium, cross the vessel wall and invade the damaged parenchyma [11, 12]. At the same time astrocytes and microglia be-
come activated. These cellular events depend on the secretion of inflammatory mediators which are produced by neural and glial cells in response to an ischaemic insult. Once activated in the site of injury inflammatory cells start to secrete a large variety of cytotoxic agents such as cytokines, chemokines and promote the expression of adhesion molecules, matrix metalloproteinases (MMPs) with an increased production of free radicals. Stress signalling pathways, such as the c-Jun N-terminal kinases (JNKs) pathway are also activated. Both the JNK pathway and pro-inflammatory mediators further potentiate the brain tissue injury and lead within hours and days to apoptotic and necrotic cell death of the potential viable tissue [13–15]. Figure 2 provides a schematic diagram illustrating the inflammatory response after ischaemic stroke.

**Gliarial cell activation**

Microglia are the resident macrophages of the brain. They are very sensitive to subtle alterations in their neuronal microenvironment. Resting microglia has a very ramified cytoplasm, covering a territory of 30–40 μm in diameter. In response to an injury, they quickly become activated and undergo morphological transformations as well as functional changes. They start to retract their long processes and their shape becomes rounded — so called phagocytotic, amoeboid microglia [16–18]. The degree of microglial activation depends on the severity of neuronal injury. The mildest injuries may only cause ramification of microglia with a bushy appearance, whereas in acute pathological cases microglia are characterised by hypertrophic bodies and less arborised processes. If neurons die, microglia transform into brain macrophages. These stimulated cells rapidly proliferate to focal sites of injury due to an increasing expression of immunoreactive cell surface molecules and to the secretion of various inflammatory molecules such as chemotactic factors which induce the recruitment of other microglial cells. Figure 3 shows the changes in microglial morphology and accumulation of activated microglia in a mouse stroke model (48 hours after transient 30 minutes middle cerebral artery occlusion). This phenomenon is accompanied by an increased expression of cytokines: interleukins (IL-1β, IL-4, IL-6, IL-10), tumor necrosis factor-α (TNFα), interferons and chemokines such as MCP-1 [19, 20]. The surrounding astrocytes are sensitive to the increased release of these immunomodulatory peptides and therefore severe ischaemia also compromises astrocytic function. Astrocytes modulate the phagocytic functions of microglia and promote the expression of adhesion molecules in the neurovascular unit on endothelial cells and circulating leukocytes [21, 22]. These early inflammatory processes are likely to be deleterious for neuron survival.

**Leukocyte infiltration**

Shortly after the onset of injury the blood brain barrier opens by the

---

**Table 1**

Classification of different vasculitis types.

<table>
<thead>
<tr>
<th>Vasculitis</th>
<th>Primary</th>
<th>Secondary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large-size arteries</td>
<td></td>
<td>Systemic lupus erythematosus ± anti-phospholipid syndrome</td>
</tr>
<tr>
<td>Giant cell temporal arteritis (Horton)</td>
<td>Behçet disease</td>
<td></td>
</tr>
<tr>
<td>Takayasu arteritis</td>
<td></td>
<td>Sjögren syndrome</td>
</tr>
<tr>
<td>Middle-size arteries</td>
<td></td>
<td>Neuro-sarcoidosis</td>
</tr>
<tr>
<td>Primary angiitis of the central nervous system</td>
<td>Rheumatoid arthritis</td>
<td></td>
</tr>
<tr>
<td>Polyarteritis nodosa</td>
<td></td>
<td>Scleroderma</td>
</tr>
<tr>
<td>Small-size arteries</td>
<td></td>
<td>Inflammatory bowel diseases</td>
</tr>
<tr>
<td>Churg Strauss</td>
<td></td>
<td>Infections, e.g., varicella-zoster virus vasculopathy</td>
</tr>
<tr>
<td>Wegener</td>
<td></td>
<td>Others</td>
</tr>
<tr>
<td>Microscopic polyarteritis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 3**

Activation and accumulation of microglia after cerebral ischaemia. Shown are examples of immunohistochemical staining for CD11b, an integrin surface marker on microglial cells, after 48 hours of reperfusion following 30 minutes middle cerebral artery occlusion (MCAo) in mice. Hyper-ramified (A, arrow heads) or activated microglia (A, white arrows) can be detected in the hippocampus (nuclei are stained in blue with DAPI). Phagocytotic microglia are present in the injured brain tissue (B, black arrows). Cresyl violet stained sections of ischemic brains are shown above, red boxes locate the immunolabelled ischaemic tissue in the hippocampus and the striatum shown in A and B. Magnification 20x. Accumulation of activated amoeboid microglia is found in the ischaemic striatum (C), while the contralateral healthy region shows no CD11b positive staining (D). The dashed red circle outlines the ischaemic tissue. Magnification 5x.
Figure 4
Therapeutic interventions targeting the inflammatory response after ischaemia. Experimental and clinically tested approaches to reduce brain damage and inflammation after stroke. In red is shown thrombolysis used to dissolve the blood clot [3]. In black, strategies to block excitotoxic pathways, such as the inhibition of glutamate receptors [53] and JNK stress signaling pathway [33, 34]. In blue are shown therapeutic interventions targeting inflammation, such as inhibitors of free radicals [41, 54, 55] and anti-inflammatory molecules [38, 40, 56–58]. And in pink other potential targets such as MMPs [59], PARP-1 [60, 61], inhibitors of caspase-1 or caspase-3 [62, 63] and erythropoietin (EPO) as a neuroprotective agent [64].

Table 2

<table>
<thead>
<tr>
<th>Target</th>
<th>Effects</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombolysis</td>
<td>tPA (alteplase)</td>
<td>Restores blood flow</td>
</tr>
<tr>
<td>Anti-excitotoxicity</td>
<td>NMDA and AMPA antagonists, channel blockers, JNKs inhibitors</td>
<td>Block excitotoxicity pathways</td>
</tr>
<tr>
<td>Anti-oxidants</td>
<td>iNOS and COX inhibitors, NXY-059</td>
<td>Free radical production inhibitors</td>
</tr>
<tr>
<td>Anti-inflammatory agents</td>
<td>Leukocytes depletion</td>
<td>Reduces the number of circulating neutrophils</td>
</tr>
<tr>
<td></td>
<td>Anti-ICAM-1 (Enlimomab)</td>
<td>Blocks leukocytes adhesion and transendothelial migration</td>
</tr>
<tr>
<td></td>
<td>TNF</td>
<td>Prevents TNF from interacting with its receptor</td>
</tr>
<tr>
<td></td>
<td>Interleukin-1 receptor antagonist (IL-1ra)</td>
<td>Prevents IL-1 from interacting with its receptor</td>
</tr>
<tr>
<td></td>
<td>Minocycline</td>
<td>Inhibits cytotoxic agents secreted by microglia</td>
</tr>
<tr>
<td>Other</td>
<td>PARP inhibition</td>
<td>Blocks cell death</td>
</tr>
<tr>
<td></td>
<td>MMP inhibition: MMP-9 knock-out mice</td>
<td>Reduction of proteolytic degradation of BBB</td>
</tr>
<tr>
<td></td>
<td>Erythropoietin (EPO)</td>
<td>Neuroprotective</td>
</tr>
<tr>
<td></td>
<td>Caspase inhibitors: Casp-1,-3</td>
<td>Inhibition of apoptosis</td>
</tr>
</tbody>
</table>
disruption of the endothelia tight junctions [23]. The release of inflammatory mediators from activated glial cells induces the expression of proteins on the outer cell membrane of vascular endothelial cells and leukocytes. The opening of the barrier and the release of inflammatory mediators leads to the migration of circulating leukocytes to the site of injury. Infiltration of leukocytes occurs in three steps: rolling on the surface of endothelial cells, adhesion to the endothelial wall and migration or diapedesis. The initial capture and migration is mediated by three main groups of cell adhesion molecules: selectins (P-, E- and L-selectins), immunoglobulins (VCAM-1, ICAM-1) and integrins (CD11a-c) [11, 24]. Circulating monocytes/macrophages are also recruited at the site of injury and will penetrate into the parenchyma. The proportion of invading macrophages in the ischaemic tissue can not be discriminate from resident activated microglia.

Activation and accumulation of leukocytes (granulocytes, monocytes/macrophages, lymphocytes) at the site of injury results in further damage. Current evidence suggests a detrimental role of inducible or immunological nitric oxide synthase (iNOS) and cylooxygenase-2 (COX-2) from neutrophils and vascular cells in the ischaemic brain [25, 26]. They induce the formation of reactive oxygen species: nitric oxide (NO) and superoxide respectively, leading to the generation of peroxinitrite [14, 27] which is a powerful oxidant which triggers damage to DNA and other cell constituents [1]. Up-regulation of pro-inflammatory molecules and reactive oxygen species after cerebral ischaemia are not the only cause of secondary injury. Expression of metalloproteinase genes is related to the presence of inflammatory cells in ischaemic tissue. A recent study has demonstrated the infiltration of metalloproteinase-9 positive (MMP-9+) neutrophils after human stroke [28]. MMP-9 is involved in the degradation of components of the extracellular matrix and basal lamina which may potentiate haemorrhagic complications after ischaemic stroke.

Transcriptional regulation of inflammation
The secretion of inflammatory molecules in cerebral ischaemia triggers the activation of several transcription factors involved in the inflammatory response. The nuclear factor-kappa B (NF-xB) when activated, induces the expression of genes encoding cell adhesion molecules, cell surface receptors and cytokines [29, 30]. Iademola and colleagues have shown an attenuation of the inflammatory response induced by focal cerebral ischaemia in mice with a null mutation in the CD36 receptor which recognises pathogens and induces an inflammatory response through the activation of NF-xB [31]. Interference with the nuclear factor-kappa B activation may therefore be beneficial to secondary ischaemic injury.

Mitogen activated protein kinases (MAPKs) are a family of key proteins which are activated in response to stress signals. MAPK signalling pathways positively regulate transcription of inflammatory genes, such as those coding for TNF-α, IL-1β, IL-6, IL-8, COX-2 (for review [9, 32]). D-JNKi-1, a specific inhibitor of the JNK pathway, was shown to induce a strong neuroprotective effect in a range of experimental cerebral ischaemia model [33, 34]. Besides, the inhibition of MAP kinases, especially p38 and JNK, could lead to a reduction in pro-inflammatory molecule production by inflammatory cells, especially microglia/macrophages in which the MAPK cascades are highly activated after an ischaemic injury [35,36]. We are therefore currently investigating the effect of D-JNKi-1 on the inflammatory response and the progression of the tissue damage after ischaemia.

Neuroprotective approaches targeting inflammation
Different strategies aimed at preventing the inflammatory response after cerebral ischaemia have been successful in rodent models. Ischaemic damage was shown to be attenuated, together with systemic leukocyte depletion by preventing the expression of, or by blocking adhesion molecules, by inhibiting pro-inflammatory cytokines or by diminishing the free radical generating enzymes iNOS or COX-2 (for review [1, 37]). Attempts to translate therapeutic interventions to stroke patients have been more disappointing than promising. For instance the selective IL-1 receptor antagonist (IL-1ra) which limits the pro-inflammatory action of IL-1, has been tested in randomised patients with acute stroke [38]. Despite a conclusive phase II study no recent publications have reported IL-1ra as a therapeutic agent for acute stroke.

More than a thousand of potential agents underwent clinical evaluation [39]. However none of these drugs have demonstrated benefit in stroke clinical trials as for instance the application of murine monoclonal anti-ICAM-1 in Enlimomab trial [40] and XF-059, a nitrone-based free radical trapping agent [41]. A non-exhaustive list of therapeutic strategies targeting especially inflammation after ischaemic stroke is shown in figure 4 and table 2.

Experimental studies to clinical trials: lost in translation
Reasons for failure have been discussed before [42] and include morphological and functional differences between rodents and humans, timing of the intervention, evaluation of efficacy, pharmacokinetic issues (plasma concentration of drugs) and side effects. Anti-inflammatory strategies have also in some cases promoted deleterious infections and fever [40].

Until now, researchers have focused mostly on the negative role of inflammation after stroke and thus have looked to therapeutic means to inhibit post-stroke
inflammation. Nevertheless, there is evidence suggesting that inflammation might also be beneficial in stroke: it is a crucial mechanism to clear damaged tissue after an infarction, it promotes angiogenesis, tissue remodelling and regeneration [1, 43]. Therefore, there is clearly the need to better understand the subtle balance between the beneficial and deleterious effects of inflammation in stroke. Furthermore, experimental studies on cerebral ischaemia have mostly target one cell type, i.e., neurons, while endothelium, astrocytes and microglia have been considerably neglected. Future research on experimental stroke models should considered the important role of non-neuronal cells and the bivalent function of inflammation. A better insight in these aspects is important before planning future clinical trials.

**Autoimmune and infectious aetiologies of stroke**

We have discussed on the inflammatory response after cerebral ischaemia and its consequences. In this second part of this review we will illustrate how a disorder affecting the immune system could lead to stroke. Therefore, we will briefly review the vasculitides which can cause stroke. Primary vasculitides is classified into three categories, depending on the size of the affected arteries. This classification is relevant for the clinician. Indeed, magnetic resonance angiography or even conventional arteriography can provide good information on large-size arteries, are of variable value in middle-size arteries vasculitis and are useless in small-size arteries vasculitis, since in the latter case, the lesions are below the threshold of detection (tab. 1). In other terms, a normal neuro-imaging study does not rule out a middle-size or a small-size arteries vasculitis. A meningeal and brain parenchymal biopsy might thus be warranted. Another important fact is that most vasculitis that can cause strokes are systemic diseases and thus other organs, including the heart, are frequently involved, for instance the Takayasu arteritis (TA) which affects the large arterial trunks. TA must always be ruled out in young patients with stroke, especially if they are female and of Asian descent. Stroke, either ischaemic or haemorrhagic occurs in 20–30% of TA. Treatment consists in a combination of corticosteroids, immunosuppressive therapies and surgery [44].

By contrast, temporal arteritis (Horton’s disease) affects elderly people (usually >60 years old) and is characterised by headaches and a high erythrocyte sedimentation rate (>50 mm/hour) (fig. 5). When suspecting Horton’s disease, one must immediately administer high doses of corticosteroids, since there is a risk of occlusion of the central artery of the retina, leading to definite loss of vision. Stroke may occur in 10% of patients with Horton’s disease. Other manifestations include fever, fatigue, jaw claudication and its very frequent association with polymyalgia rheumatica. Of importance, temporal artery biopsy, which is the gold standard diagnostic procedure, remains positive up to 7–10 days after corticosteroids were started. The duration of corticosteroid therapy depends on the erythrocyte sedimentation rate and the clinical symptoms. Usually, the treatment lasts a minimum of one year [45].

Primary angiitis of the central nervous system (PACNS) is a rare condition, but very difficult to diagnose. Indeed, in contrast to other vasculitides, PACNS affects only the vessels of the brain (middle-size arteries), without any other systemic manifestations. Its mode of presentation is variable including, in addition to ischaemic or haemorrhagic strokes, confusion, cognitive deterioration, headaches, etc. Extensive
blood tests are not contributory. Cerebrospinal fluid examination is abnormal in 50–90% of cases, but of little help, since it shows only aspecific findings, i.e., a mild to moderate increase in proteins, and/or leucocytes, and/or erythrocytes.

Nevertheless, if a PACNS is suspected, it is of importance to establish the diagnosis as the treatment is heavy, consisting in long-term corticosteroids and cyclophosphamide. Therefore, a meningeal and parenchymal brain biopsy is often necessary [46].

We will not address here the other primary vasculitis causing stroke (tab. 1), as strokes are relatively rare in those vasculitidis and, usually, other organs are affected before the central nervous system. The same is true for secondary vasculitis. Nevertheless, it is worth to mention here the problem of the anti-phospholipid syndrome (aPLs). Indeed, this condition is found in 40% of the cases of systemic lupus erythematosus, but can also be primary, i.e., not associated with any underlying condition. aPLs may cause arterial and venous thrombosis. Typical manifestations include: spontaneous abortion beyond 10 week of gestation, cardiac valve abnormalities, thrombocytopenia, haemolytic anaemia. A neurological involvement is frequent, consisting in strokes, migraine-like phenomenon, chorea, and transverse myelopathy. The diagnosis of aPLs is based on the Sapporo criteria established in 1999 and revised in 2004 in Sydney. Detailing these diagnostic criteria would be well beyond the purpose of this small review and we advise the avid reader to consult the following references: [47–49].

From a neurological standpoint, it is recommended to rule out an aPLs in patients younger than 45 years-old who present with an ischaemic stroke. But it is crucial to follow the above-mentioned modified Sapporo criteria in order to avoid over-diagnosis of aPLs. Indeed, this diagnosis often implies a long-term anticoagulation treatment [50].

Conclusion

Our knowledge on pathophysiology of cerebral ischaemia has greatly improved because of experimental in vitro and in vivo studies. A large number of drugs have been developed in the purpose to inhibit the complex cascade taking place after stroke including excitotoxicity and inflammation. Despite those efforts none of the potential therapeutic agent has been successful in clinical trials so far.

In this short review we have shown that inflammation can cause an occlusion of a brain artery and therefore drive to cerebral ischaemia, as well as be the direct consequence of stroke and exacerbate damage. Furthermore, stroke induces immunodepression and favors opportunistic infections such as bronchopneumonia [51].

Therefore, in stroke therapy there is a great need to identify new approaches which could block the detrimental inflammatory response as well as inducing neuroprotection or perhaps in combination with thrombolysis.

Acknowledgments

We thank Melanie Price for helpful comments.

References
